Crispr Therapeutics AG vs Powell Industries — how do they compare? Crispr Therapeutics AG trades at $51.2 (market cap $4.88B), while Powell Industries trades at $192.23 (market cap $6.89B). The key difference: Powell Industries is the larger of the two by market cap, and Powell Industries pays a 0.19% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Powell Industries for 4 Days on average.
| CRSP | POWL | |
|---|---|---|
Market Cap | $4.88B | $6.89B |
Volume | 2,861,747 | 728,725 |
Sector | Health | Industrials |
52-Week High | $74.92 | $322.05 |
52-Week Low | $44.34 | $94.02 |
Typical Hold Time | 77 Days | 4 Days |
Enterprise Value | $3.30B | $6.26B |
Dividend Yield | — | 0.19% |
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% on the day, with a bearish technical signal and negative profitability metrics. The company reported no revenue in 2025 with a net loss of $581.60M, though recent earnings beat expectations in Q2 2026. Analyst sentiment remains positive with a $67.83 price target and 57.9% buy ratings, supported by upcoming clinical data catalysts for its gene-editing therapies.
The stock faces significant fundamental challenges with negative margins and cash burn, but strong analyst support and pipeline progress offer long-term potential. Key risks include clinical trial outcomes and commercialization execution, while institutional interest and positive media coverage provide near-term catalysts for investor consideration.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →Powell Industries designs and manufactures electrical equipment and engineered solutions for power distribution and control. Its products are used across energy, utility, industrial, and commercial infrastructure.
Read more on POWL →